Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + oxaliplatin + 5-fluorouracil + leucovorin
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin. This regimen has been studied for the treatment of locally advanced pancreatic cancer and metastatic colorectal cancer. The drugs are typically administered on a biweekly schedule with specific dosing protocols. Studies have shown moderate activity in advanced pancreatic cancer (median OS 14.5 months) and metastatic colorectal cancer (average OS 22 months). Common side effects include hematological toxicity (neutropenia) and sensory neuropathy.
- Other names
- GOLF regimen
02
Targets
DNARNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on gemcitabine + oxaliplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + oxaliplatin + 5-fluorouracil + leucovorin.